-+ 0.00%
-+ 0.00%
-+ 0.00%

Citigroup Maintains Buy on Catalyst Pharmaceuticals, Raises Price Target to $33

Benzinga·11/07/2025 20:53:34
Listen to the news
Citigroup analyst Samantha Semenkow maintains Catalyst Pharmaceuticals (NASDAQ:CPRX) with a Buy and raises the price target from $31 to $33.